Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744076 | 0.93 | UTS2R (0.63) | UTS2R | |
| SCHEMBL5744589 | 0.90 | UTS2R (0.65) | UTS2R | |
| SCHEMBL5743906 | 0.90 | UTS2R (0.65) | UTS2R | |
| SCHEMBL5744178 | 0.89 | UTS2R (0.54) | UTS2RSTS | |
| SCHEMBL5744992 | 0.89 | UTS2R (0.54) | UTS2RSTS | |
| SCHEMBL6820497 | 0.88 | UTS2R (0.59) | UTS2R | |
| SCHEMBL6820505 | 0.88 | UTS2R (0.59) | UTS2R | |
| SCHEMBL6819512 | 0.86 | UTS2R (0.67) | UTS2R | |
| SCHEMBL5743168 | 0.86 | UTS2R (0.67) | UTS2R | |
| SCHEMBL5835448 | 0.86 | UTS2R (0.66) | UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385840-B1 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2006-10-04 | — | — | EP | claimed |
| US-7091204-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | claimed |
| EP-1385840-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | claimed |
| US-20040152891-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | claimed |
| EP-1385840-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2002090348-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| EP-1385840-B1 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7091204-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1385840-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20040152891-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| EP-1385840-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090348-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152891-A1 | Sulfonamides | UTS2R, PRSS2, STS | UTS2R 1/4885STS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.